Opposition to IP protection for COVID-19 vaccines, therapies, tests and other technologies may only prevent eradication and treatment of the disease.
Kevin E. Noonan
Advertisement
Kevin E. Noonan, PhD, is a partner at McDonnell Boehnen Hulbert & Berghoff LLP.
Articles by Kevin E. Noonan
A controversial naming convention attempts to explain important distinctions between biologic drugs and their biosimilar counterparts.
Advertisement
Latest Updated Articles
Biosimilar Names Prove Difficult to DefinePublished: March 1st 2017 | Updated:
Advertisement
Advertisement
